|
1
|
Wang T, Chen T, Niu H, Li C, Xu C, Li Y,
Huang R, Zhao J and Wu S: MicroRNA-218 inhibits the proliferation
and metastasis of esophageal squamous cell carcinoma cells by
targeting BMI1. Int J Mol Med. 36:93–102. 2015.PubMed/NCBI
|
|
2
|
Xu S, Little PJ, Lan T, Huang Y, Le K, Wu
X, Shen X, Huang H, Cai Y, Tang F, et al: Tanshinone II-A
attenuates and stabilizes atherosclerotic plaques in
apolipoprotein-E knockout mice fed a high cholesterol diet. Arch
Biochem Biophys. 515:72–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang J, Jiang Q, Wan L, Yang K, Zhang Y,
Chen Y, Wang E, Lai N, Zhao L, Jiang H, et al: Sodium tanshinone
IIA sulfonate inhibits canonical transient receptor potential
expression in pulmonary arterial smooth muscle from pulmonary
hypertensive rats. Am J Respir Cell Mol Biol. 48:125–134. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang X, Wei Y, Yuan S, Liu G, Lu Y, Zhang
J and Wang W: Potential anticancer activity of tanshinone IIA
against human breast cancer. Int J Cancer. 116:799–807. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang HS, Zhang FJ, Li H, Liu Y, Du GY and
Huang YH: Tanshinone IIA inhibits human esophageal cancer cell
growth through miR-122-mediated PKM2 down-regulation. Arch Biochem
Biophys. 598:50–56. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qiu S, Granet R, Mbakidi JP, Brégier F,
Pouget C, Micallef L, Sothea-Ouk T, Leger DY, Liagre B, Chaleix V,
et al: Delivery of tanshinone IIA and α-mangostin from
gold/PEI/cyclodextrin nanoparticle platform designed for prostate
cancer chemotherapy. Bioorg Med Chem Lett. 26:2503–2506. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu M, Wang C and Wang J: Tanshinone I
induces human colorectal cancer cell apoptosis: The potential roles
of Aurora A-p53 and survivin-mediated signaling pathways. Int J
Oncol. 49:603–610. 2016.PubMed/NCBI
|
|
8
|
Kim EO, Kang SE, Im CR, Lee JH, Ahn KS,
Yang WM, Um JY, Lee SG and Yun M: Tanshinone IIA induces TRAIL
sensitization of human lung cancer cells through selective ER
stress induction. Int J Oncol. 48:2205–2212. 2016.PubMed/NCBI
|
|
9
|
Sanders DA, Ross-Innes CS, Beraldi D,
Carroll JS and Balasubramanian S: Genome-wide mapping of FOXM1
binding reveals co-binding with estrogen receptor alpha in breast
cancer cells. Genome Biol. 14:R62013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahmed M, Hussain AR, Siraj AK, Uddin S,
Al-Sanea N, Al-Dayel F, Al-Assiri M, Beg S and Al-Kuraya KS:
Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in
inducing anticancer effects in colorectal cancer cells. Mol Cancer.
14:1312015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang N, Xie Y, Li B, Ning Z, Wang A and
Cui X: FoxM1 influences mouse hepatocellular carcinoma metastasis
in vitro. Int J Clin Exp Pathol. 8:2771–2778. 2015.PubMed/NCBI
|
|
12
|
Zhang J, Zhang J, Cui X, Yang Y, Li M, Qu
J, Li J and Wang J: FoxM1: A novel tumor biomarker of lung cancer.
Int J Clin Exp Med. 8:3136–3140. 2015.PubMed/NCBI
|
|
13
|
Zhang Y, Li CF, Ma LJ, Ding M and Zhang B:
MicroRNA-224 aggrevates tumor growth and progression by targeting
mTOR in gastric cancer. Int J Oncol. 49:1068–1080. 2016.PubMed/NCBI
|
|
14
|
Kim HY, Cho Y, Kang H, Yim YS, Kim SJ,
Song J and Chun KH: Targeting the WEE1 kinase as a molecular
targeted therapy for gastric cancer. Oncotarget. Jun 23–2016.(Epub
ahead of print). doi: 10.18632/oncotarget.10231.
|
|
15
|
Kanda M, Shimizu D, Fujii T, Tanaka H,
Tanaka Y, Ezaka K, Shibata M, Takami H, Hashimoto R, Sueoka S, et
al: Neurotrophin receptor-interacting melanoma antigen-encoding
gene homolog is associated with malignant phenotype of gastric
cancer. Ann Surg Oncol. 23 Suppl 4:S532–S539. 2016. View Article : Google Scholar
|
|
16
|
Kanda M, Shimizu D, Fujii T, Tanaka H,
Shibata M, Iwata N, Hayashi M, Kobayashi D, Tanaka C, Yamada S, et
al: Protein arginine methyltransferase 5 is associated with
malignant phenotype and peritoneal metastasis in gastric cancer.
Int J Oncol. 49:1195–1202. 2016.PubMed/NCBI
|
|
17
|
Han TS, Hur K, Xu G, Choi B, Okugawa Y,
Toiyama Y, Oshima H, Oshima M, Lee HJ, Kim VN, et al: MicroRNA-29c
mediates initiation of gastric carcinogenesis by directly targeting
ITGB1. Gut. 64:203–214. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu ZL, Wang JN, Wu XH, Xie HJ, Han Y, Guan
YT, Qin Y and Jiang JM: Tanshinone IIA prevents rat basilar artery
smooth muscle cells proliferation by inactivation of PDK1 during
the development of hypertension. J Cardiovasc Pharmacol Ther.
20:563–571. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang C, Du X, Yang R, Liu J, Xu D, Shi J,
Chen L, Shao R, Fan G, Gao X, et al: The prevention and treatment
effects of tanshinone IIA on oestrogen/androgen-induced benign
prostatic hyperplasia in rats. J Steroid Biochem Mol Biol.
145:28–37. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tan X, Yang Y, Cheng J, Li P, Inoue I and
Zeng X: Unique action of sodium tanshinone II-A sulfonate (DS-201)
on the Ca2+ dependent BKCa activation in mouse cerebral arterial
smooth muscle cells. Eur J Pharmacol. 656:27–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu Q, Sheng L, Yang M, Zhu M, Huang X and
Li Q: Tanshinon IIA injection accelerates tissue expansion by
reducing the formation of the fibrous capsule. PLoS One.
9:e1057562014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jing X, Xu Y, Cheng W, Guo S, Zou Y and He
L: Tanshinone I induces apoptosis and pro-survival autophagy in
gastric cancers. Cancer Chemother Pharmacol. 77:1171–1181. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu M, Cao FL, Li NY, Liu YQ, Li YP and Lv
CL: Tanshinone IIA reverses the malignant phenotype of SGC7901
gastric cancer cells. Asian Pac J Cancer Prev. 14:173–177. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Li JX, Wang YQ and Miao ZH:
Tanshinone I inhibits tumor angiogenesis by reducing Stat3
phosphorylation at Tyr705 and hypoxia-induced HIF-1α accumulation
in both endothelial and tumor cells. Oncotarget. 6:16031–16042.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin JY, Ke YM, Lai JS and Ho TF:
Tanshinone IIA enhances the effects of TRAIL by downregulating
survivin in human ovarian carcinoma cells. Phytomedicine.
22:929–938. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang CY, Hua L, Sun J, Yao KH, Chen JT,
Zhang JJ and Hu JH: MiR-211 inhibits cell proliferation and
invasion of gastric cancer by down-regulating SOX4. Int J Clin Exp
Pathol. 8:14013–14020. 2015.PubMed/NCBI
|
|
27
|
Gormally MV, Dexheimer TS, Marsico G,
Sanders DA, Lowe C, Matak-Vinković D, Michael S, Jadhav A, Rai G,
Maloney DJ, et al: Suppression of the FOXM1 transcriptional
programme via novel small molecule inhibition. Nat Commun.
5:51652014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Song IS, Jeong YJ, Jeong SH, Heo HJ, Kim
HK, Bae KB, Park YH, Kim SU, Kim JM, Kim N, et al: FOXM1-induced
PRX3 regulates stemness and survival of colon cancer cells via
maintenance of mitochondrial function. Gastroenterology.
149:1006–1016.e9. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Buchner M, Park E, Geng H, Klemm L, Flach
J, Passegué E, Schjerven H, Melnick A, Paietta E, Kopanja D, et al:
Identification of FOXM1 as a therapeutic target in B-cell lineage
acute lymphoblastic leukaemia. Nat Commun. 6:64712015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wiseman EF, Chen X, Han N, Webber A, Ji Z,
Sharrocks AD and Ang YS: Deregulation of the FOXM1 target gene
network and its coregulatory partners in oesophageal
adenocarcinoma. Mol Cancer. 14:692015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Katoh M and Katoh M: Human FOX gene family
(Review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
|
|
32
|
Hui MK, Chan KW, Luk JM, Lee NP, Chung Y,
Cheung LC, Srivastava G, Tsao SW, Tang JC and Law S: Cytoplasmic
Forkhead box M1 (FoxM1) in esophageal squamous cell carcinoma
significantly correlates with pathological disease stage. World J
Surg. 36:90–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang Z, Zhang G and Kong C: FOXM1
participates in PLK1-regulated cell cycle progression in renal cell
cancer cells. Oncol Lett. 11:2685–2691. 2016.PubMed/NCBI
|
|
34
|
Inoguchi S, Seki N, Chiyomaru T, Ishihara
T, Matsushita R, Mataki H, Itesako T, Tatarano S, Yoshino H, Goto
Y, et al: Tumour-suppressive microRNA-24-1 inhibits cancer cell
proliferation through targeting FOXM1 in bladder cancer. FEBS Lett.
588:3170–3179. 2014. View Article : Google Scholar : PubMed/NCBI
|
